The Outcome of Sorafenib Therapy on Unresectable Hepatocellular Carcinoma: Experience of Conversion and Salvage Hepatectomy
The Outcome of Sorafenib Therapy on Unresectable Hepatocellular Carcinoma: Experience of Conversion and Salvage Hepatectomy
复制标题
DOI：
10.21873/anticanres.12250
复制
发表时间：
2018-01-01
影响因子：
2
通讯作者：
Shimada, Mitsuo
中科院分区：
文献类型：
--
作者：
Yoshimoto, Toshiaki;Imura, Satoru;Shimada, Mitsuo
背景/目的：我们报告了在我科接受索拉非尼治疗晚期肝细胞癌的结果。患者和方法：对2009-2015年间应用索拉非尼治疗的38例不能切除的肝细胞癌患者进行了回顾性研究。结果：1年总生存率为59.3%。宏观血管侵犯和有效率是影响患者生存的独立预后因素。索拉非尼术后手术切除2例获得长期生存。病例1：1例局部不能切除的肝细胞癌患者在索拉非尼治疗下表现出明显的反应，可以进行完全的手术切除。该肿瘤FGF4检测呈阳性。病例2：有肝细胞癌切除病史的患者有多处远处转移。大多数病灶在索拉非尼治疗后缩小，残肝和残肺转移灶新的病灶被切除。对索拉非尼耐药的皮损FGF4均为阴性。结论：在索拉非尼有效的情况下，索拉非尼联合手术切除治疗晚期肝癌是可行的。
Background/Aim: We report the outcomes of sorafenib therapy for advanced hepatocellular carcinoma (HCC) in our Department. Patients and Methods: Thirty-eight patients with unresectable HCC who were administrated sorafenib from 2009 to 2015 were investigated retrospectively. Results: The 1-year overall survival rate was 59.3%. The macroscopic vascular invasion and response rate were independent prognostic factors of survival. Surgical resection after sorafenib achieved long-term survival in two cases. Case 1: A patient with locally unresectable HCC showed significant response induced by sorafenib, which allowed complete surgical resection. This tumor tested positive for FGF4. Case 2: A patient with a history of hepatectomy for HCC had multiple distant metastases. Most lesions were reduced in size after sorafenib therapy and new lesions in the remnant liver and residual lung metastases were resected. The sorafenib-resistant lesions were negative for FGF4. Conclusion: Sorafenib combined with surgical resection is a feasible option in advanced HCC patients, if sorafenib has been effective.